The Massachusetts Biotechnology Council (MassBio) has entered an expanded partnership with Veolia North America for its savings and rewards program, MassBio Edge.
Veolia will serve as the Preferred Partner for all streams of waste management. The company will be an all-inclusive resource for transportation, disposal, training, and regulatory guidance related to all types of hazardous, non-hazardous, regulated medical waste, and low-level radioactive materials, and will offer comprehensive recycling and waste to energy programs.
"Our members are developing the next generation of breakthrough therapies and as the pace of innovation accelerates, improving patient outcomes should remain at the crux of their work, not concerns over medical and pharmaceutical waste disposal," said Jason Cordeiro, Vice President of Edge Operations, MassBio. "With this expanded partnership, we are excited to provide our members consolidated waste management services so they can have the peace of mind to focus on what they do best."
As a one-stop-shop for all MassBio members, Veolia provides a complete range of services for life sciences, biotechnology, universities, hospitals, industrial and municipal customers needing to dispose of their waste. With more than 45 sales, services, treatment and disposal facilities in the United States, the company provides a full array of capabilities and facilities conveniently located to most industrial facilities throughout the country.
"The proper management and recycling of waste is critical to the future success of the life sciences and we're looking forward to working with MassBio's vast membership to provide dependable waste management services, reduce their environmental footprint, provide regulatory guidance and support the advancement of the industry," said Bob Cappadona, Executive Vice President and Chief Operating Officer of Veolia North America. "We're thrilled to continue our successful partnership with MassBio and facilitate additional savings for the most innovative companies so they can further invest in research and development."
